polyposis but not in unaffected relatives or unrelated people. 4 In some cases DNA isolated from the tumours of patients without familial adenomatous polyposis but with colorectal carcinoma also showed somatic mutations in the gene. 4 How will these advances affect clinical practice? In people with a family history of familial adenomatous polyposis prenatal or postnatal testing should be able to identify whether a mutation has been inherited. This will avoid some of the problems of linkage testing which is relevant where incomplete pedigrees reduce the value of linkage analysis, which occurred in two thirds of the families reported on by MacDonald et al. 8 Screening the general population for new mutations is probably impracticable because of the rarity of the condition.
The main impact of this work should be on the understanding of the pathogenesis of sporadic colorectal carcinoma, although this is more complicated. Other somatic mutations contribute to the development of sporadic colorectal cancer,'°01 including the ras oncogene,'2 the p53 oncosuppressor gene on chromosome 17, 13 and the gene deleted in colon cancer on chromosome 22.1' Moreover, the effects of mutant oncosuppressor genes, including that coding for familial adenomatous polyposis, are exposed by the loss of the remaining normal version of the gene in the allelic pair. 1113 15 How these genetic abnormalities fit together in the development of the tumour, what the familial adenomatous polyposis protein does in the cell, and why mutations lead to the formation of polyps are all unknown. Different inherited mutations of the gene coding for familial adenomatous polyposis are likely to be found in some people with a family history ofcolonic cancer (but not of adenomatous polyposis). 6 Ultimately this research may offer the possibility of presymptomatic investigation and intervention in people with an increased risk of sporadic colonic cancer. During the past decade controversy has existed about the effects of adjuvant systemic treatment on overall survival in patients with operable breast cancer, mainly because of the small size of clinical tests. To decide which current treatments confer benefit has required collating individual data on 75 000 women from 133 clinical trials.' The overview clearly showed that adjuvant treatment with ovarian ablation, tamoxifen, or polychemotherapy produced benefit. Perhaps the biggest surprise was the continuously increasing survival benefit for patients more than five years after treatment with adjuvant systemic therapy.
The overview was derived exclusively from randomised clinical trials; unfortunately, only a few patients with breast cancer have been entered into such trials. To obtain adequate statistical power to refute the null hypothesis that treatment had no effect the overview therefore included trials that were not simply comparisons of a particular treatment with nontreatment. For example, the tamoxifen overview included trials comparing tamoxifen and cytotoxic drugs with cytotoxic drugs alone. Many patients included in the treatment group of each overview therefore received a more complex adjuvant treatment, only one component of which was the subject of the overview. Although legitimate statistically,2 this may have understated the size of the effect of treatment.
The evaluations of ovarian ablation, cytotoxic drugs, and tamoxifen included trials conducted at different times. Ovarian ablation was the first of these modalities tested. Although patients in these trials had the longest follow up, data on oestrogen receptors were not available when patients were entered into the trials. The earliest trials of chemotherapy evaluated single agents, sometimes given in short perioperative courses, but neither of these approaches is now considered to be optimal. More recent trials have concentrated on polychemotherapy and tamoxifen. Obviously, characteristics of the patients may have affected chosen treatments; the three overviews are therefore too different to allow direct comparison and cannot be used as the basis for deciding individual treatment.
Another important observation was the unequivocal finding of an overall survival benefit from adjuvant ovarian ablation in younger women. This procedure has been virtually abandoned during the past decade on the assumption that its benefit was limited to delaying recurrence. But problems remain in determining its proper use: the results apply only to women under 50 years old and its side effects in this group BMJ VOLUME 304cannot be ignored. Too few patients were available for evaluation of possible long term adverse effects, such as those on bone density and vascular disease. Most studies were conducted before measurement of oestrogen receptors became available so its value in selecting patients remains a matter of conjecture. No data were available to determine whether adding chemotherapy or tamoxifen to ovarian ablation might provide additional benefit. Finally, the newer alternatives to surgical or radiotherapeutic castration, such as agonists to luteinising hormone releasing hormone, were not assessed.
The overview showed an unequivocal survival advantage after polychemotherapy, though the benefits seemed less in older women. The overview did not provide any data relevant to whether chemotherapy might offer more benefits to particular postmenopausal patients, perhaps those with tumours testing negative for oestrogen receptors.
Of the three modalities reviewed, chemotherapy is perceived as the most toxic. Deciding whether its use is justified depends on the assessment of the patient and her doctor of its side effects and benefits. If asked, patients are willing to accept toxic treatment in exchange for quite modest gains in overall survival, well within the range of benefits described within the overview.3 5 Furthermore, studies have suggested that the more toxic treatments offer better quality adjusted survival.67
The overview of cytotoxic drugs concentrated on polychemotherapy. The regimens studied varied greatly and were presumably of variable efficacy. Thus the average effect reported in the overview is likely to be less than that achievable with the best current regimens. In general, the overview supported the superiority of combination chemotherapy over treatment with a single agent. None of the trials, however, investigated single agent anthracycline, which is very active as a primary treatment for large tumours. 8 The overview of tamoxifen was the largest of the three and showed a clear benefit for tamoxifen, particularly among patients with tumours positive for oestrogen receptors. Some benefit, however, was still observed in patients whose tumours were reported as being negative for oestrogen receptors. Owing to the statistical procedures used this overview may have underestimated the value of tamoxifen as a single treatment in younger women. Thus adjuvant tamoxifen may benefit all patients, but it alone may not be the optimal treatment in each case (in combination with cytotoxic drugs might be better), and its optimal duration has yet to be defined.
What is the way forward? Studies should focus on combining different modalities within subgroups according to the oestrogen receptor content of their primary tumour. The use of combined tamoxifen and chemotherapy in younger women requires particular attention. Further uncertainty concerns the distribution of benefit among treated patients. Combined treatment with tamoxifen and chemotherapy in patients with positive nodes saves an estimated 12 lives per 100 women after 10 years of follow up.' This by no means implies, however, that 88 patients gain nothing from having received the treatment. In fact, a reduction of 30% in the odds of death are completely compatible with an effect of treatment which prolongs the lives of all patients. On this assumption, treated patients would gain an average of four months of additional survival in the first five years and one year within the first 10 years of follow up.79 Although an equal share of treatment benefit among all patients is unlikely, assuming that a substantial proportion of patients fail to benefit from adjuvant treatment is unwise.
The overview represents a considerable achievement made possible only by the participation of patients and their doctors in randomised clinical trials. Breast cancer is a heterogeneous disease, many therapeutic options are available, and long follow up is needed to identify the benefits of treatment. We should ensure that future overviews can address unconfounded comparisons of treatment within defined groups of patients. Results from such overviews will be much more useful in selecting the right treatments for individual patients.
To achieve this, many more patients will need to participate in clinical trials. Patients entered into such trials receive either the best standard treatment or an experimental treatment intended to increase efficacy or reduce morbidity, or both. Participating doctors and patients may be assured that care is not being compromised. Clinical research in breast cancer must become the treatment of choice'0 if we are to fulfil our shared obligation to provide the best treatment for each patient. RICHARD 
